日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

神经胶质生物标志物在未接受口服抗凝治疗的房颤患者缺血性卒中和其他心血管事件风险评估中的应用

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P; Eikelboom, John W; Kultima, Kim; Oldgren, Jonas; Wallentin, Lars; Burman, Joachim

Plasma Profiles of Neuroglial Injury Biomarkers after Ischemic Stroke

缺血性卒中后神经胶质损伤生物标志物的血浆谱

Sjölin, Karl; Röyter, Björn; Forgo, Bianka; Aulin, Julia; Kultima, Kim; Lindbäck, Johan; Ström, Jakob O; Burman, Joachim

Anticoagulation and antiplatelet strategies used in Sweden in patients with myocardial infarction and concomitant atrial fibrillation: nationwide cohort study

瑞典对合并房颤的心肌梗死患者使用的抗凝和抗血小板治疗策略:一项全国性队列研究

Aulin, Julia; Modica, Angelo; Lindhagen, Lars; Alfredsson, Joakim; Held, Claes; James, Stefan; Batra, Gorav

Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

心房颤动患者血清神经丝轻链

Sjölin, Karl; Aulin, Julia; Wallentin, Lars; Eriksson, Niclas; Held, Claes; Kultima, Kim; Oldgren, Jonas; Burman, Joachim

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial.

即使考虑生物标志物的预后影响,肥胖对房颤预后的影响仍然存在悖论:来自 ARISTOTLE 试验的启示

Sandhu Roopinder K, Ezekowitz Justin A, Hijazi Ziad, Westerbergh Johan, Aulin Julia, Alexander John H, Granger Christopher B, Halvorsen Sigrun, Hanna Michael S, Lopes Renato D, Siegbahn Agneta, Wallentin Lars